Adam Knight is the founder of Neuron23. Neuron23 has raised $114M in total funding. Latest round: Series B. Based in South San Francisco, United States.
Neuron23 was founded in late 2018 by neuroscientist Dr. Nancy Stagliano and Adam Knight. The company focuses on developing precision medicines for genetically defined neurological and immunological diseases, primarily targeting Parkinson's disease. Their approach integrates data science, human genetics, machine learning-based patient selection, and functional genomics.
Full founder directory · Investor directory · Company funding database · Fundraising library